NL-OMON47906
Completed
Phase 4
Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands - Third MMR vaccine dose in young adults (acronym: MMR-3)
RIVM0 sites150 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Mumps infection
- Sponsor
- RIVM
- Enrollment
- 150
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy young adult 18\-25 years of age., Previously been immunized with two
- •doses of the MMR vaccine according to the Dutch NIP (MMR\-1 at \~14 months and
- •MMR\-2 at \~9 years).
Exclusion Criteria
- •Medical conditions that will severely affect immunological responses to
- •vaccinations, such as, but not limited to, cancer or an immune disorder.,
- •Vaccination should be postponed during any illness with fever \>38\.5°C until the
- •fever has disappeared., Vaccination with any vaccine during the first two weeks
- •before and four weeks after MMR\-3\., An additional MMR vaccination during the
- •study., Coagulation disorder and/or anticoagulant medication. , Be or have been
- •under immunosuppressive medical treatment, like cytostatics, high\-dose
- •corticosteroids, immune globulins, blood or plasma transfusions that might
- •interfere with the results of the study (within the previous 3 months)., Have
- •or previously had clinical symptoms of mumps virus infection., Have or
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulinesNL-OMON51004Erasmus MC, Universitair Medisch Centrum Rotterdam44
Completed
Phase 2
A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levelsabnormal cholesterol valuesdyslipidemia10013317NL-OMON40373Kowa Research Europe52
Completed
Phase 3
A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension period in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatmentdiabetesDiabetes mellitus type 210018424NL-OMON38357Boehringer Ingelheim18
Completed
Phase 3
A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infantsNL-OMON49743Pfizer14
Completed
Phase 3
A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)adenocarcinoma of the pancreaspancreatic cancer10015674NL-OMON41730Incyte Corporation12